Incidence of clinical AIDS conditions in a cohort of homosexual men with CD4+ cell counts < 100/mm3. Multicenter AIDS Cohort Study.

Incidence of clinical AIDS conditions in a cohort of homosexual men with CD4+ cell counts < 100/mm3. Multicenter AIDS Cohort Study.
复制标题

CD4 细胞计数 < 100/mm3 的同性恋男性队列中临床艾滋病状况的发病率。

DOI:
10.1093/infdis/170.5.1284
复制
发表时间:
1994
期刊:
The Journal of infectious diseases
影响因子:
--
通讯作者:
Vermund,SH
Vermund,SH
中科院分区:
--
文献类型:
--
作者:
Bacellar,H;Muñoz,A;Hoover,DR;Phair,JP;Besley,DR;Kingsley,LA;Vermund,SH

文献摘要

被引文献

相似文献

描述了按抗逆转录病毒药物和化学预防分组的CD 4细胞/mm 3 ≤ 100的患者中艾滋病的发病率。数据来自2646名感染人类免疫缺陷病毒1型的同性恋男性。参与者在1985-1993年期间参加了多中心艾滋病队列研究。卡氏肺孢子虫肺炎的发病率为每100人-年47.4,未经治疗,21.5与抗逆转录病毒药物单独和12.8与抗逆转录病毒药物联合预防。对于卡波西肉瘤,这些比率分别为23.2、11.3和15.1。在接受卡氏肺孢子虫肺炎预防治疗的人群中,一些机会性感染(包括鸟分枝杆菌复合体、非视网膜炎巨细胞病毒病和巨细胞病毒视网膜炎)的发生率增加,因为这种肺炎的发生率降低,寿命延长。在接受治疗的患者中,艾滋病界定疾病的发病率模式表明艾滋病流行正在发生变化,需要新的治疗方法。这些数据与临床试验的开发和规划以及医疗保健提供者特别相关。
Incidence rates of AIDS illnesses are described among patients with≤ 100 CD4 cells/mm 3 grouped by use of antiretrovirals and chemoprophylaxis. Data were obtained from 2646 homosexual men infected with human immunodeficiency virus type 1. Participants were in the Multicenter AIDS Cohort Study during 1985-1993. The incidence rates per 100 person-years for Pneumocystis carinii pneumonia were 47.4 without treatment, 21.5 with antiretrovirals alone, and 12.8 with antiretrovirals combined with chemoprophylaxis. For Kaposi’s sarcoma these rates were 23.2, 11.3, and 15.1, respectively. The incidence of some opportunistic infections, including Mycobacterium avium complex, nonretinitis cytomegalovirus disease, and cytomegalovirus retinitis, increased among persons receiving P. carinii pneumonia prophylaxis, because of reduction of this pneumonia and extension of life span. The incidence pattern of AIDS-defining illnesses in patients receiving treatment points to the changing AIDS epidemic and the need for new therapies. The data are particularly relevant to the development and planning of clinical trials and to health care providers.